Novo Nordisk Securities Class Action Lawsuit Alert

The Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025, and July 28, 2025, of the important September 30, 2025, lead plaintiff deadline in the ongoing class action lawsuit. The lawsuit alleges that Novo Nordisk provided false and misleading statements about its growth potential and GLP-1 market penetration. Investors who purchased securities during this period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.

Key Takeaways:

• The lawsuit alleges that Novo Nordisk provided false and misleading statements about its growth potential and GLP-1 market penetration.
• The class period is between May 7, 2025, and July 28, 2025, both dates inclusive.
• Investors who purchased securities during this period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
• A class action lawsuit has already been filed, and investors who wish to serve as lead plaintiff must move the Court no later than September 30, 2025.
• The Rosen Law Firm, which represents investors throughout the globe, has a track record of success in securities class actions and shareholder derivative litigation.
• The firm has secured over $438 million for investors in 2019 alone and was ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Statistics:

• Class period: May 7, 2025, to July 28, 2025
• Lead plaintiff deadline: September 30, 2025
• Amount secured for investors in 2019: Over $438 million
• Number of securities class action settlements in 2017: 304 (according to ISS Securities Class Action Services)

Sources:

• Newsfile Corp. - September 15, 2025
• ISS Securities Class Action Services (for 2017 settlement data)
• The Rosen Law Firm, P.A. website (for details on firm's track record and achievements)